Early Phase 2a data suggest the IPF therapy GRI-0621 alters gene activity tied to inflammation, scarring, and tissue repair.

It took a while for columnist Kylene Henderson's husband, Donnie, to be diagnosed with an autoimmune disease that led to ...

The activity levels of four genes linked to the Notch pathway could help in achieving an earlier diagnosis of idiopathic ...

Pulmonary fibrosis (PF), as its name suggests, is a disease marked by scarring — or fibrosis — of the lungs, leading to shortness of breath. PF is part of a larger group of more than 200 lung ...

Kylene Henderson lives in the rural Midwest with her husband, Donnie, and their two school-age daughters. In 2022, after a year-long investigation into his symptoms, Donnie was diagnosed with ...

Note: This column describes the author’s own experiences with Protonix (pantoprazole), Prograf (tacrolimus), Rapamune (sirolimus), and Forteo (teriparatide injection). Not everyone will have the same ...

Pulmonary fibrosis (PF) is characterized by the accumulation of scar tissue (fibrosis) in the lungs. Idiopathic pulmonary fibrosis (IPF), a form of the disease that lacks a clear cause, is the most ...

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...

On New Year’s Day, my daughters and I created vision boards for 2026. If you haven’t made one before, a vision board is a collage of images, quotes, and art that captures your goals and intentions for ...

Building on positive Phase 2 data, Puretech Health plans to launch a Phase 3 trial in the coming months to further test its experimental oral therapy deupirfenidone (LYT-100) in people with idiopathic ...

BMS-986020 is an anti-fibrotic drug being developed by Bristol-Myers Squibb, and is chemically a lysophosphatidic acid (LPA) receptor antagonist. The drug, an oral formulation, is in clinical trials ...